Alzamend Neuro plans to initiate the first of five Phase II clinical trials for AL001, a novel lithium-delivery system, in healthy human subjects during the second quarter of 2025. This study, conducted in partnership with Massachusetts General Hospital, will compare AL001 to currently available lithium treatments, focusing on lithium’s pharmacokinetics in the brain and blood. The goal is to demonstrate AL001’s potential to improve lithium delivery to the brain while minimizing systemic side effects.
This trial is important because it could revolutionize lithium therapy, a cornerstone treatment for bipolar disorder and increasingly relevant in Alzheimer’s, major depressive disorder, and PTSD. Current lithium treatments require burdensome therapeutic drug monitoring (TDM) due to a narrow therapeutic window and potential toxicity. If AL001 proves to be effective and safer, with less need for TDM, it could significantly expand lithium’s clinical utility and improve patient compliance, potentially impacting millions of patients.
The study will leverage a novel head coil developed by Tesla Dynamic Coils BV, crucial for precise measurement of lithium distribution in the brain. Preclinical studies in mice have already suggested AL001’s superior brain absorption and lower blood lithium levels. Alzamend aims to confirm these findings in humans and establish a foundation for future trials in patients with neurological and psychiatric disorders. A previously completed Phase IIA study in Alzheimer’s patients and healthy subjects has already established a maximum tolerated dose for AL001, designed to minimize the need for TDM.
This first Phase II study represents a crucial step in Alzamend’s development of AL001. Positive results could validate the drug’s novel approach to lithium delivery and accelerate its progression towards later-stage clinical trials. Ultimately, Alzamend envisions AL001 as a next-generation lithium treatment offering improved safety, efficacy, and patient convenience, potentially transforming the treatment landscape for a range of mental health conditions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
